Industry Briefs: June 4, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Briefs: June 4, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.


Company News

AMRI Burlington has been contracted as an aseptic fill manufacturer for the market introduction of Cardium Therapeutics’s and its subsidiary, Tissue Repair Company’s, wound-care product Excellagen. Read More

Baxter International has entered into an agreement with Chatham Therapeutics for development and commercialization of Chatham’s Factor IX hemophilia B gene-therapy treatment. Read More

Bayer HealthCare has formed a partnership with Covance for clinical drug development, including R&D services related to Phase II–IV clinical studies and central laboratory services. Read More

Bristol-Myers Squibb has partnered with 10 cancer-research centers in immuno-oncology. Read More

Catalent Pharma Solutions has signed a definitive agreement to sell its US commercial-packaging operations based in Philadelphia, Pennsylvania, and Woodstock, Illinois, to a company affiliated with Frazier Healthcare. The transaction is subject to certain closing conditions and is expected to close in the next few months. Read More

Forest Laboratories and Nabriva Therapeutics have entered into a $25-million agreement for the development of Nabriva’s novel antibacterial agent, BC-3781. Read More

Genmab and Novartis have agreed to use Genmab’s DuoBody technology platform to create and develop bispecific antibodies. Read More

JHP Pharmaceuticals has entered into an agreement with an undisclosed pharmaceutical company to produce the clinical and commercial supply of an innovative injectable used in the cardiovascular setting. Read More

Mylan has received FDA approval to launch a generic version of Pfizer’s Lipitor (atorvastatin calcium). Read More

WuXi PharmTech has commented on the conviction of a former employee for the theft of Merck compounds. Read More

People News

BioStorage Technologies has appointed Kristina Robson as senior director of comprehensive solutions. Read More

William G. Kaelin, Jr. has been elected to Eli Lilly's board of directors. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy

Click here